<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076175</url>
  </required_header>
  <id_info>
    <org_study_id>IM047-001</org_study_id>
    <secondary_id>2021-002308-11</secondary_id>
    <nct_id>NCT05076175</nct_id>
  </id_info>
  <brief_title>A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis</brief_title>
  <official_title>A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063)&#xD;
      in causing and maintaining clinical remission. Ozanimod will be administered orally to&#xD;
      pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an&#xD;
      inadequate response to conventional therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 29, 2021</start_date>
  <completion_date type="Anticipated">January 13, 2031</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who achieve clinical remission</measure>
    <time_frame>At Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve clinical remission</measure>
    <time_frame>At Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve clinical response</measure>
    <time_frame>At Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve clinical response</measure>
    <time_frame>At Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve symptomatic remission</measure>
    <time_frame>At Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achievement of symptomatic remission</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve endoscopic improvement</measure>
    <time_frame>At Week 10 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve corticosteroid free remission</measure>
    <time_frame>At Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs leading to discontinuation from treatment</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs of interest</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state systemic exposure of ozanimod and CC112273</measure>
    <time_frame>At Week 18 and throughout the study, up to 70 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in Absolute Lymphocyte Count (ALC)</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in ALC</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Ozanimod High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ozanimod Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozanimod</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Ozanimod High Dose</arm_group_label>
    <arm_group_label>Ozanimod Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit: www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderately to severely active Ulcerative Colitis (UC) diagnosed prior to the Screening&#xD;
             Visit&#xD;
&#xD;
          -  Evidence of UC extending beyond the rectum, as determined by baseline endoscopy&#xD;
&#xD;
          -  Has had an inadequate response, loss of response to, or is intolerant to at least 1 of&#xD;
             the following treatments for UC: oral aminosalicylates, systemic corticosteroids,&#xD;
             immunomodulators, biologic therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Crohn's disease or indeterminate colitis&#xD;
&#xD;
          -  Has documentation of positive test for toxin producing Clostridium difficile, or&#xD;
             polymerase chain reaction examination of the stool&#xD;
&#xD;
          -  Apheresis within 2 weeks of randomization&#xD;
&#xD;
          -  History of or currently active primary or secondary immunodeficiency, or participants&#xD;
             with known genetic disorders as a cause for colitis&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain the NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>1138431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Ozanimod</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ozanimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

